Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatment of primary plasma cell leukemia in patients under 70 years
2009-016607-33Phase 2Active
- Sponsor
- CHU Amiens-Picardie
- Start
- Nov 2009
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, single-arm trial of bortezomib, lenalidomide and pegylated liposomal doxorubicin in Plasma cell leukemia (pPCL), sponsored by CHU Amiens-Picardie. Primary endpoints: progression-free survival, disease-free survival and 4 more. Started Nov 2009; status: active.
02
Drugs
bortezomiblenalidomidepegylated liposomal doxorubicin
03
Conditions
Plasma cell leukemia (pPCL)
Beyond the preview
Go deeper on 2009-016607-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016607-33.